Abstract
Hydroxyurea (HU), a cytotoxic agent used in myeloproliferative disorders, has recently been introduced as an adjunct to combination anti-retroviral therapy. We describe abnormal nail pigmentation in four HIV-seropositive patients treated with HU and discuss the likely factors associated with its development.
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Black People
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1
-
Humans
-
Hydroxyurea / adverse effects*
-
Hydroxyurea / therapeutic use
-
Hyperpigmentation / chemically induced*
-
Male
-
Middle Aged
-
Nails / pathology*
-
Nucleic Acid Synthesis Inhibitors / adverse effects*
-
Nucleic Acid Synthesis Inhibitors / therapeutic use
Substances
-
Anti-HIV Agents
-
Nucleic Acid Synthesis Inhibitors
-
Hydroxyurea